MULTIPLE myeloma patients are now able to access Pharmaceutical Benefits Scheme-subsidised therapy in the form of a newly reimbursed triple treatment option combining Revlimid (lenalidomide) in combination with bortezomib (V) and dexamethasone (d).
Designated as RVd, it's the first time in Australia that the major treatment options for myeloma have been reimbursed as a triplet therapy.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jun 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jun 20
